A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

BACKGROUND: Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, would complement anti-tumor activity of durvalumab, a PD-L1 inhibitor, and the 3-dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Alexandra S., Nichols, Erin, Cimino-Mathews, Ashley, Peer, Cody, Cao, Liang, Lee, Min-Jung, Kohn, Elise C., Annunziata, Christina M., Lipkowitz, Stanley, Trepel, Jane B., Sharma, Rajni, Mikkilineni, Lekha, Gatti-Mays, Margaret, Figg, William D., Houston, Nicole D., Lee, Jung-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657373/
https://www.ncbi.nlm.nih.gov/pubmed/31345267
http://dx.doi.org/10.1186/s40425-019-0680-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657373/
https://www.ncbi.nlm.nih.gov/pubmed/31345267
http://dx.doi.org/10.1186/s40425-019-0680-3

Ejemplares similares